Navigation Links
Echo Therapeutics Announces 2010 Financial Results

FRANKLIN, Mass., March 21, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the year ended December 31, 2010.  Echo's Annual Report on Form 10-K is available through Echo's website at

Corporate Highlights:

  • In February 2010, Echo Therapeutics, Inc. announced an additional advance in the product design of Symphony with the development of its next generation electronic component package. This important advance included an initial 33% reduction in component size and improved architectural design as compared to the prototype electronic package of the Company's earlier Symphony tCGM device.
  • Echo Therapeutics' needle-free Symphony tCGM System was profiled in a March 31, 2010 online article in Scientific American Magazine entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," which discusses the importance of continuous glucose monitoring.  Another article, "Echo Therapeutics' Needle-Free Symphony Continuous Glucose Monitoring System," was featured in the November 29, 2010 issue of Diabetes Health Magazine.
  • In August 2010, following final product development work of the Prelude SkinPrep System, Echo Therapeutics and Ferndale Pharma Group successfully completed a clinical trial that determined the efficacy of Prelude in enhancing the onset of activity of 4% lidocaine cream.
  • In November 2010, Echo Therapeutics' licensing partner, Ferndale Pharma Group, submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the Prelude SkinPrep System and 4% lidocaine cream.

  • "We made very tangible progress during 2010 on all of our key programs and we achieved some very important milestones, including the successful submission of a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for our Prelude device to enhance the delivery of 4% topical lidocaine cream with our partner Ferndale Pharma Group," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "Additionally, we raised significant capital to fund our operations aggressively through final development."

    Fiscal Year 2010 Financial ResultsFor fiscal year 2010, the Company was principally involved with the product development and clinical studies of its Prelude SkinPrep System. Through licenses with Ferndale and Handok, the company recognized license fee revenue amortization of approximately $226,000 for fiscal 2010.  During fiscal year 2010, the Company received approximately $245,000 in other income related to a federal grant under the Qualified Therapeutic Discovery Projects Grants Program.  The Company's operating expenses for fiscal year 2010 of $5.3 million decreased by approximately $0.5 million compared with fiscal year 2009.  The net loss for fiscal 2010 was $4.1 million, or ($0.15) per share, compared to a net loss of $11.0 million, or ($0.61) per share for fiscal 2009.  The Company reported a cash balance of approximately $5.1 million as of March 18, 2011 as a result of equity financings completed during the period January 2011 to March 18, 2011.2011 OutlookEcho Therapeutics' management reiterated its expectations for the 2011 outlook:

    "As we continue to build on our positive momentum, we are focused on completing several key milestones during 2011 that we believe will significantly increase shareholder value.  We anticipate a listing on a national exchange in the near-term which will allow us to maximize our outreach to a new, untapped investor base.  Additionally, we hope to gain product clearance for our Prelude System with our licensee Ferndale which will enable the company to begin generating near-term revenue," Dr. Mooney concluded. "This year we plan to aggressively advance our clinical development of our Symphony system, clearing the path for an application to the FDA for marketing clearance. We anticipate securing additional strategic partner licensing arrangements while we begin manufacturing scale-up for Prelude's product validation and planned product launch in the second half of 2011."

    About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for use in hospital critical care units and for patients with diabetes. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

    Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.  Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its licensees' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its licensees' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems.  These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2011, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

    Media: Richard SternChairman and Chief Executive Officer

    Stern & Co.(508) 530-0329

    (212) 888-0044Connect With Us:- Visit our website at

    - Follow us on Twitter at

    - Join us on Facebook at


    SOURCE Echo Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
    2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
    3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
    5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
    6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
    7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
    8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
    9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
    10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
    11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
    Post Your Comments:
    (Date:11/29/2015)... , Nov. 29, 2015  Strengthening its leadership ... PHG, AEX: PHIA) today announced IntelliSpace Portal 8.0 ... analytics and visualization platform that helps radiologists detect, diagnose ... 2015 Radiological Society of North America Annual Meeting ... IntelliSpace Portal 8.0 helps address the changing demands in ...
    (Date:11/29/2015)... , Nov. 29, 2015  At this year,s ... to experience the most complete mobile C-arm portfolio with ... is Ziehm Vision RFD 3D, the world,s only 3D ... edge length per scan volume. In addition, Ziehm Imaging ... motorized mobile C-arm in four axes which is ideally ...
    (Date:11/29/2015)... 29, 2015 CIVCO Medical Solutions will ... the Radiological Society of North America ... November 29 – December 4, 2015. ... offer customers unrivaled versatility, enhanced user experience and ... --> ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... ... 2015 , ... The American Society for Clinical Pathology (ASCP) announced today that ... On Nov. 30, ASCP shared its “Give a minute. Get tested. Find a cure.” ... importance of getting tested for HIV. , ASCP has asked members to replace their ...
    (Date:11/30/2015)... Beach, FL (PRWEB) , ... November 30, 2015 ... ... of Consumer Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer ... and even more so for a child’s exposure limits. , The original Nov ...
    (Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... scoop often results in wasted time. Fortunately, an inventor from Chesterfield, Va., has found ... SCOOP CLIP to keep the scoop used to measure powdered contents in a canister ...
    (Date:11/30/2015)... ... 2015 , ... Medicalis, a leading developer of enterprise-scale Imaging ... (RSNA) annual meeting, being held November 29 – December 3, 2015, that its ... company has completed installations for Integrated Delivery Network (IDN) customers such as WellSpan, ...
    (Date:11/30/2015)... ... November 30, 2015 , ... ... its industry-leading suite of automated breast density assessment and enterprise analytics solutions, ... November 29-December 4, 2015 (South Hall booth #2377). Volpara’s quantitative breast imaging ...
    Breaking Medicine News(10 mins):